Galderma announced the FDA approval of Restylane® Lyft for cheek augmentation and the correction of age-related midface contour deficiencies late last week. So what is this exciting new product? Well……it’s basically Perlane®, which has been available for years, but rebranded. Perlane® is a hyaluronic acid filler that was used mainly in the nasolabial fold areas, but was also used in the central face area for adding volume to the cheeks. It is a thicker HA filler than its sister product, Restylane®.
Due to the large success of Voluma®, a hyaluronic acid filler for the midface region which is distributed by Allergan, Galderma had decided to resubmit Perlane to the FDA for approval for use in the midface, as many physicians were using it there anyway. Thus, Restylane® Lyft is now the first and only FDA approved filler indicated to provide fullness to the midface area (cheeks) and to correct and smooth the nasolabial folds (“smile lines”). Galderma is currently undergoing new package changes, but expect to see Perlane® packaging remain for awhile as the product is the exact same. In my practice, I’m sure I will continue using Perlane®, er Restylane® Lyft, as I always have, and I very much doubt it will change the industry that much.
